Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France.

Trial Profile

Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Saxagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms DIAPAZON
  • Sponsors AstraZeneca; Bristol-Myers Squibb
  • Most Recent Events

    • 23 Sep 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 06 Aug 2013 Planned end date changed from 1 Jul 2014 to 1 May 2015 as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Actual initiation date (May 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top